| Similar Articles |
 |
Bio-IT World November 2005 Kevin Davies |
A Win-Win Situation The inaugural Bridging Discovery and IT conference explored critical issues facing discovery, clinical, and IT teams struggling to communicate and collaborate in biopharma organizations.  |
Bio-IT World April 2007 Vicki Glaser |
Software Solutions for Medicinal Chemistry Driven by advances in chemical synthesis, instrumentation, and high-throughput and high-content screening technology, medicinal chemistry's transition from an art to a science is benefiting from a wealth of new software products, spanning both bio- and cheminformatics.  |
Bio-IT World April 15, 2003 Mark D. Uehling |
Target Elimination Industry and FDA scientists turn to databases, applications software, and laboratory chips to move the safest, most effective molecules into clinical trials.  |
Chemistry World June 1, 2012 Derek Lowe |
Peace, love and understanding You'd think that the chemists and biologists working in drug discovery would understand each other pretty well by now. You would be wrong about that.  |
Bio-IT World March 2006 Mike May |
The Evolving Grid Computing System at J&J Johnson & Johnson is planning to double the size of its grid computing network and the number of applications that run on it by the end of this year, according to company executives.  |
Bio-IT World May 2006 Mike May |
Drug Discovery As Easy As Pie A Johnson & Johnson pharmaceutical researcher has developed a software application that takes data from a compound, compares it to best-case values, and codes related measurements with color to assess the compound's potential as a drug.  |
BusinessWeek April 17, 2006 Amy Barrett |
J&J: Reinventing How It Invents Johnson & Johnson bets on a new push for product development as a cure for its ailing stock.  |
BusinessWeek October 10, 2005 |
J&J: How A Dealmaker Nurtures Newcomers Johnson & Johnson has a good track record for retaining employees after a takeover. The company's broadly decentralized structure, which gives managers great leeway - no small thing for execs used to running their own shows.  |
BusinessWeek September 30, 2009 Arlene Weintraub |
J&J Tries to Buy Itself a Pipeline It's snapping up biotechs, spearheading innovative alliances, and reshuffling R&D.  |
The Motley Fool November 26, 2007 Brian Orelli |
Johnson & Johnson Reorganizes -- Who Wins? Johnson & Johnson announces the second phase of its reorganization plan. While it may take years to see whether the measures will help J&J, some other companies could benefit far more quickly.  |
The Motley Fool October 12, 2007 Billy Fisher |
Dueling Fools: Johnson & Johnson Bear Rebuttal The bears say that J&J is a good company, but will underperform looking forward.  |
The Motley Fool January 24, 2006 Stephen D. Simpson |
Shake a Leg, J&J! J&J isn't a perfect story, but investors who buy today and hold for a while will be happy they did.  |
BusinessWeek June 18, 2007 Arlene Weintraub |
J&J's New Baby As other divisions stumble, Johnson & Johnson's consumer products - bolstered by a $16.6 billion addition - provide a security blanket.  |
The Motley Fool November 22, 2006 Brian Lawler |
Dueling Fools: Johnson & Johnson Bear Rebuttal The bottom line is that investors are putting their faith in the ability of J&J's management to acquire its way to renewing top-line growth in the coming years.  |
The Motley Fool November 22, 2006 Steven Mallas |
Dueling Fools: Johnson & Johnson Bull There are many ways to expose one's portfolio to the health-care industry. But J&J offers the best upside potential at relatively little risk.  |
BusinessWeek June 18, 2007 Arlene Weintraub |
Johnson & Johnson's Next Baby? J&J could use an infusion of new drugs and devices from an acquisition such as Boston Scientific.  |
The Motley Fool January 12, 2006 Stephen D. Simpson |
The Guidant Auction Continues Johnson & Johnson hopes to save the deal with a last-minute raise of its offer. Although Boston Scientific's offer is $4 per share higher, that doesn't necessarily make it the best value. Investors, take note.  |
The Motley Fool November 15, 2005 Stephen D. Simpson |
Guidant, J&J Kiss and Make Up The two companies hammered out a revised merger agreement that continues J&J's buyout of Guidant, but at a lower price. So what does this mean for the med-tech space, assuming that this deal actually goes through? Investors, take note.  |
The Motley Fool September 17, 2010 James Early |
Today's Buy Opportunity: Johnson & Johnson The case for Johnson & Johnson is very simple: Here's a company that's been around forever, that pays a 3.5% dividend, and that's spread across arguably the most necessary sector (behind water and sewage): health care.  |
BusinessWeek December 20, 2004 Amy Barrett |
J&J: Don't Stop Dealmaking Now For years, health-care giant Johnson & Johnson has held on-again, off-again acquisition talks with medical-device maker Guidant Corp. But now, patent expirations and a thin pipeline mean the giant needs more than just Guidant.  |
BusinessWeek January 30, 2006 Robert Barker |
Guidant Or No, J&J Is A Buy To Wall Street, Johnson & Johnson has been sounding like Dumb & Dumber.  |
BusinessWeek April 23, 2007 Arlene Weintraub |
Under The Weather At J&J Johnson & Johnson's three big products have seen setbacks, with little in sight to replace them.  |
The Motley Fool May 2, 2011 Anupama Pattanaik |
J&J Attempts to Create Major "Synthes"-is Johnson & Johnson will acquire the medical device maker for $21.3 billion.  |
Bio-IT World November 2006 Kevin Davies |
Building a Bridge Over Pharma with IT More than 100 enthusiastic delegates bridging the full breadth of the drug development pipeline gathered recently for the second annual Bridging Pharma and IT conference. Here are some highlights.  |
Bio-IT World February 2006 John Russell |
Marvelous Models of Biological Systems Here are highlights from a roundtable discussion with researchers representing academia and pharmaceuticals, as well as executives from modeling technology providers on whether or not Pharma is ready to bet on computational modeling of biological systems.  |
The Motley Fool August 24, 2010 Matt Koppenheffer |
How Much Is Johnson & Johnson Worth? Is Johnson & Johnson's stock on sale?  |
The Motley Fool May 20, 2011 Andrea Kalvesmaki |
Johnson & Johnson's Billion-Dollar Move Orthopedics are the name of the game for this company's future earnings.  |
The Motley Fool November 3, 2005 Stephen D. Simpson |
The At-Odds Couple Johnson & Johnson seems to want out, but Guidant looks willing to grab the shotgun to see that this union is completed. Investors, should the deal fall through, look for J&J to continue shopping and don't be surprised if Guidant attracts attention from Abbott Labs or Boston Scientific.  |
The Motley Fool April 13, 2006 Doug Short |
A Foolish Baby Shower: Johnson & Johnson If you're an advocate of these two rules -- "It's never too early to start investing" and "Invest in what you know" -- then here is an ideal pick for baby's first stock.  |
The Motley Fool July 28, 2011 Melly Alazraki |
J&J or Novartis? Novartis' businesses are an investor's delight; J&J's improving but isn't there yet.  |
Fast Company March 2014 Adam Bluestein |
Will Johnson & Johnson's New Innovation Centers Point The Way Toward Its Future? To visit the southeastern quadrant of Cambridge, Massachusetts, these days is to witness the rise of a new kind of city -- a glassy, gleaming pharmopolis dedicated to the discovery, development, and marketing of drugs.  |
The Motley Fool November 22, 2006 Brian Lawler |
Dueling Fools: Johnson & Johnson Bear J&J's dividend does provide investors with some degree of income, but a CD does, too -- without a health-care stock's risks.  |
The Motley Fool July 26, 2005 Rich Smith |
J&J: One Pricey Stock This giant of the health-care world reported its second quarter 2005 earnings last week but, by all appearances, failed to impress Wall Street. Johnson & Johnson's become very big, very pricey.  |
The Motley Fool December 31, 2007 Brian Orelli |
Best Stock for 2008: Johnson & Johnson Down on its luck for 2007, here's why Johnson & Johnson's stock will rebound in 2008.  |
The Motley Fool March 24, 2011 Anand Chokkavelu |
Rising Star Buy: Johnson & Johnson It's time to buy shares of Johnson & Johnson, the "health-care mutual fund."  |
The Motley Fool October 12, 2007 Ryan Fuhrmann |
Dueling Fools: Johnson & Johnson Bull The bullish opinion on J&J is that the company is handling current difficulties well, and the low stock price makes for a bargain for investors.  |
The Motley Fool November 22, 2006 Steven Mallas |
Dueling Fools: Johnson & Johnson Bull Rebuttal Plenty of opportunities lie ahead for Johnson & Johnson, and even in down times, you've got a good defensive stock.  |
The Motley Fool April 13, 2004 Alyce Lomax |
J&J Makes the Day It may be over a hundred years old, but the company reports a spry first quarter.  |
Chemistry World August 22, 2013 Phillip Broadwith |
J&J buys Aragon's prostate cancer arm Hormonally-driven cancer drug discovery specialist Aragon Pharmaceuticals has been bought by Johnson & Johnson.  |
The Motley Fool October 7, 2010 Anand Chokkavelu |
How Johnson & Johnson Really Makes Money Hint: It's not Tylenol.  |
The Motley Fool January 13, 2006 Stephen D. Simpson |
Once More With Guidant In the ongoing game of tit-for-tat, Boston Scientific ups its bid for Guidant. This battle will ultimately be decided by the 800-pound gorilla that is J&J. Investors, take note.  |
The Motley Fool October 26, 2011 |
A Brief History of Johnson & Johnson's Returns J&J shares are much more reasonably valued today than they were ten years ago; shareholders are unlikely to experience the same going forward.  |
BusinessWeek April 17, 2006 Amy Barrett |
Unclogging J&J's Pipeline Maker of coronary stents Johnson & Johnson needs to release more products and grab back its lead in the crowded market it created.  |
The Motley Fool January 20, 2004 Alyce Lomax |
Is J&J Pain-Free? Fourth-quarter revenues surge, but rivals are waiting in the wings.  |
Chemistry World October 1, 2014 Phillip Broadwith |
J&J to buy antiviral specialist Alios Johnson and Johnson has agreed to buy antiviral specialist Alios BioPharma for $1.75 billion  |
The Motley Fool November 29, 2007 Anders Bylund |
Mano a Mano Over Johnson & Johnson A look back at the past year at Johnson & Johnson.  |
The Motley Fool January 28, 2011 Anand Chokkavelu |
10 Core Stocks: A Johnson & Johnson Update The steady reliability of J&J stock will comfort the core of your portfolio when the market gets a boo-boo.  |
The Motley Fool June 26, 2006 Stephen D. Simpson |
J&J Makes an Expensive Deal J&J announced that it has reached an agreement with Pfizer to acquire the latter's consumer health-care business for $16.6 billion in cash. Consumer health is a fine business line, but is it worth this much money? Investors, take note.  |
The Motley Fool January 26, 2005 Rich Smith |
J&J: Dialing for Dollars It pays to be big in a weak dollar world. Just ask Johnson & Johnson. Still, in the year to come, investors will want to keep one eye on J&J's operational performance, and the other on the U.S. Dollar's exchange rates against foreign currencies.  |
The Motley Fool February 24, 2004 Alyce Lomax |
J&J, Guidant Join Forces With intense rivalry looming, is a competitive partnership in vain?  |